# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Booker T. Washington (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI017-SYN
- Date: 2026-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Whitfield, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

One-week blood pressure and kidney safety check. **S**

## History of present illness

Mr. Washington returns one week after starting amlodipine and losartan for severe hypertension with stage G3b chronic kidney disease. His home readings, taken twice daily, have fallen from above 200 systolic to the 160s and 170s over 100s. He has had one mild frontal headache this week, fewer than before, and no chest pain, breathlessness, weakness, confusion, or sudden change in vision. His palpitations are less frequent. He has had no lightheadedness on standing and no ankle swelling, and he takes both medicines every morning. His reading vision is still blurred and he still gets up twice a night to urinate. He asks how to keep to the plan on travel days. His nephrology consultation, kidney ultrasound, and echocardiogram were done today. **S**

| Element | Detail |
|---|---|
| Home blood pressure | 160s to 170s over 100s, down from above 200 systolic |
| Symptoms | One mild headache this week; palpitations less frequent |
| Warning signs | No chest pain, breathlessness, weakness, confusion, or sudden vision change |
| Medication tolerance | No lightheadedness or ankle swelling |
| Adherence | Every dose taken |
| Patient goal | A plan that works on travel days |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by midafternoon; weight stable |
| Eyes | Positive | Reading vision blurred, unchanged; no sudden loss of vision |
| Cardiovascular | Positive | Occasional palpitations, less frequent; no chest pain or ankle swelling |
| Respiratory | Negative | No breathlessness |
| Genitourinary | Positive | Up twice a night to urinate; no dysuria or blood in the urine |
| Neurological | Positive | One mild frontal headache; no weakness, numbness, confusion, or lightheadedness on standing |

6 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg oral tablet, one tablet by mouth daily **S**
- Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 172/104 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 71 kg; BMI 24.6 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 22 mmol/L; BUN: 36 mg/dL (high); Creatinine: 2.2 mg/dL (high); eGFR: 34 mL/min/1.73 m² (low); Glucose: 95 mg/dL; LVEF by echocardiogram: 60%. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Bicarbonate (total CO2): 21 mmol/L (low) at baseline, 22 mmol/L at this visit **S**
- BUN: 34 mg/dL (high) at baseline, 36 mg/dL (high) at this visit **S**
- Creatinine: 2.1 mg/dL (high) at baseline, 2.2 mg/dL (high) at this visit **S**
- eGFR: 36 mL/min/1.73 m² (low) at baseline, 34 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 92 mg/dL at baseline, 95 mg/dL at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**
- Hepatitis B vaccine (HepB-CpG), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert, articulate, and in no distress |
| Blood pressure | 172/104 mmHg, the average of two seated readings after five minutes' rest with a validated cuff |
| Eyes | Undilated fundi show the arteriolar narrowing seen last week; no hemorrhages or papilledema |
| Heart | Regular rhythm, rate 82; S4; no murmur |
| Lungs | Clear |
| Extremities | No edema |
| Neurological | Fluent speech; no focal deficit |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe hypertension with hypertensive kidney disease, improving** (I12.9). Blood pressure 172/104 mmHg, down from 212/128 a week ago, with no symptoms of acute target-organ damage, but still far above target. The echocardiogram today shows concentric left ventricular hypertrophy with an ejection fraction of 60 percent. **S**
   - Increase losartan to 100 mg daily.
   - Continue amlodipine 10 mg daily.
   - Home readings twice daily; emergency department warning signs reviewed again.
   - Travel plan: medicines in his carry-on bag, a home cuff on trips, and low-sodium choices when eating out.
2. **Chronic kidney disease stage G3b A3** (N18.32). One week after starting losartan, creatinine is 2.2 mg/dL (up 5 percent from 2.1), eGFR 34, and potassium 4.6 mmol/L. Urine albumin-creatinine ratio 820 mg/g at diagnosis, so his risk category is very high. Both kidneys are small (9.4 and 9.6 cm) and echogenic without hydronephrosis, which fits long-standing hypertensive nephrosclerosis. Nephrology agrees with the plan. **S**
   - Start dapagliflozin 10 mg daily: eGFR is above 20 and albuminuria above 200 mg/g.
   - Accept a creatinine rise of up to 30 percent with losartan and dapagliflozin.
   - Potassium and creatinine at the three-week check.
   - Avoid NSAIDs; sick-day rule: hold dapagliflozin and losartan on any day with vomiting, diarrhea, or poor fluid intake, and call.
   - Pneumococcal conjugate vaccine and hepatitis B vaccine dose 1 today.
3. **Hypertensive retinopathy, both eyes** (H35.033). Arteriolar narrowing and arteriovenous nicking without hemorrhages, exudates, or papilledema on last week's dilated examination; reading blur unchanged. **S**
   - Dilated eye examination yearly.
   - Report any sudden change in vision at once.
4. **Mild anemia of chronic kidney disease** (D63.1). Hemoglobin 12.6 g/dL with ferritin 210 ng/mL and transferrin saturation 26 percent: iron replete. **S**
   - Hemoglobin at least yearly while in stage G3.
5. **Hyperlipidemia** (E78.5). Atorvastatin 20 mg started a week ago for LDL cholesterol 138 mg/dL, as recommended for adults 50 and older with eGFR below 60; no muscle symptoms. **S**
   - Continue atorvastatin; no routine repeat LDL, per KDIGO.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine (basic metabolic panel) | 2 to 4 weeks after starting or titrating losartan, dapagliflozin, or a diuretic; with each eGFR draw | Completed today | One week after starting losartan, earlier than the CMID window because of severe hypertension and eGFR 36; the care plan uses one to four weeks. Potassium 4.6, creatinine 2.2 mg/dL (up 5 percent), eGFR 34, bicarbonate 22 |
| Laboratory | Potassium and creatinine after today's changes | 2 to 4 weeks after titrating losartan or starting dapagliflozin | Due | Losartan doubles and dapagliflozin starts today; drawn at the three-week check |
| Laboratory | eGFR and urine albumin-creatinine ratio | About 3 times a year for G3b A3 | Up to date | Urine albumin-creatinine ratio 820 mg/g at diagnosis; repeat once the regimen is complete |
| Laboratory | Calcium, phosphate, and PTH | Every 6 to 12 months in G3b | Up to date | Calcium 9.1, phosphate 4.2, PTH 92 pg/mL (mildly raised) at diagnosis; next at the six-month review |
| Laboratory | 25-hydroxyvitamin D | Once at baseline | Due | Not drawn at diagnosis; PTH is mildly raised. To be drawn with the six-month calcium, phosphate, and PTH |
| Laboratory | Urinalysis with microscopy | At diagnosis, then with a change in status | Deferred | Not on file from the diagnostic workup, a deviation from the protocol. It screens for blood or casts that would point away from hypertensive nephrosclerosis. Today's ultrasound and the history fit hypertensive kidney disease, so no harm is evident. Corrective action: obtain it if albuminuria does not fall on treatment or kidney function changes unexpectedly |
| Laboratory | Hemoglobin | At least yearly in G3 | Up to date | 12.6 g/dL at diagnosis; iron studies show iron-replete anemia of chronic kidney disease |
| Survey | Kidney failure risk equation, 2 and 5 years | Yearly in G3 to G5; before referral decisions | Deferred | Not calculated before the nephrology referral, a deviation from the protocol. The referral stood on other criteria (eGFR below 60 with severely increased albuminuria), so no harm resulted. Corrective action: calculate at the six-month review, once eGFR has settled on full therapy |
| Referral | Nephrology consultation | eGFR below 60 with persistent A3 albuminuria | Completed today | Seen today; agrees with the plan |
| Imaging | Kidney ultrasound | At diagnosis when chronicity or obstruction is in question; not for routine surveillance | Completed today | Kidneys 9.4 and 9.6 cm and echogenic, without hydronephrosis: chronic kidney disease, not obstruction |
| Imaging | Transthoracic echocardiogram | At diagnosis for stage 2 hypertension or suspected left ventricular hypertrophy | Completed today | Concentric left ventricular hypertrophy; ejection fraction 60 percent |
| Imaging | 12-lead ECG | At diagnosis | Up to date | Sinus rhythm with left ventricular hypertrophy by voltage last week |
| Examination | Funduscopic examination | Yearly in chronic hypertension | Up to date | Dilated examination last week; next in a year |
| Examination | Standardized office blood pressure | Every visit; target systolic below 120 when tolerated | Completed today | 172/104 mmHg |
| Examination | Weight, BMI, and cardiac auscultation | Every visit | Completed today | 71 kg, BMI 24.6; S4 without murmur |
| Laboratory | HbA1c and TSH | HbA1c yearly; TSH at diagnosis | Up to date | HbA1c 5.4 percent and TSH 1.8 at diagnosis |
| Survey | PHQ-9 | Yearly in hypertension | Up to date | Score 4 at diagnosis |
| Medication safety | Medication review: NSAID avoidance and kidney dosing | Every visit | Completed today | No NSAIDs or over-the-counter products; doses checked for eGFR 34 |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Completed today | PCV20 and hepatitis B vaccine dose 1 given today; influenza vaccine given last fall |
| Self-management | Home blood pressure log, sodium below 2 g a day, and activity | Every visit | Completed today | Home log reviewed; travel plan agreed |

## Goal progress

- Lower blood pressure below 130/80 within two months. In progress; target 2026-06-29. **S**
- Reach a standardized office systolic pressure below 120 when tolerated by the six-month review. In progress; target 2026-10-26. **S**
- Reduce the urine albumin-creatinine ratio by at least 30 percent by the six-month review. In progress; target 2026-10-26. **S**
- Keep eGFR decline after starting therapy within 30 percent and stable thereafter. In progress; target 2026-10-26. **S**

## Medication changes

- Stopped: Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Started: Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Started: Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (KDIGO)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (KDIGO)
- CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026), Aether Forge

## Follow-up

- Three-week check with potassium and creatinine after the losartan increase and dapagliflozin start. **S**
- Next scheduled visit 2026-06-01: three-week check after losartan titration and dapagliflozin start. **S**
